Healthcare Costs Prevented Almost 40 Million Americans from Filling Their Prescriptions in 2008

Manhattan ResearchNearly 40 million U.S. adults decided not to fill a prescription medication from a doctor in the past year because of the cost, according to pharmaceutical and healthcare market research company Manhattan Research’s Cybercitizen Health™ v8.0 consumer study and strategic advisory service. The study found that women and patients with neurological and mental health conditions were the most likely to give up their medication due to cost.

For those struggling to afford healthcare, online channels have become increasingly important resources. Over 145 million consumers are online for health, and this year's Cybercitizen Health™ study saw the Internet surpass doctors as the top source for obtaining health and medical information.

Top Condition Groups Who Report Not Filling a Prescription Because of the Cost

1. Fibromyalgia
2. Inflammatory Bowel Disease
3. Generalized Anxiety Disorder
4. Chronic Bronchitis
5. Chronic Pain
6. Acute Pain
7. Adult ADHD
8. Anxiety Disorder/Social Phobia
9. Bipolar Disorder
10. Depression
Among U.S. adults (18+)
Source: Cybercitizen Health™ v8.0 (2008)

"Healthcare costs and accessibility are major barriers for Americans, and many are turning to the Internet as an alternative resource for managing their health and making treatment decisions," said Meredith Abreu Ressi, Vice President of Research at Manhattan Research. "While the Internet is an invaluable health resource for patient education and support, it doesn't replace the expertise of a trained medical professional. Healthcare providers, pharmaceutical companies, and other organizations can use online media to inform consumers of the importance of professional medical attention to their long-term health and to raise awareness of patient assistance programs."

Complimentary "State of eHealth" Report
For those interested in learning the latest trends of consumers using the Internet for health, Manhattan Research offers its "State of eHealth" report. Topics include the evolving consumer media mix, search engines for health information, and patients engaging in Health 2.0. To access the report, visit http://www.manhattanresearch.com/research/white-papers/state-of-ehealth.aspx

About Cybercitizen Health™ v8.0
Cybercitizen Health™ v8.0 was fielded in Q3 2008 among 8,714 U.S. adults (ages 18+). This consumer market research and strategic advisory service focuses on how consumers use new media and technology for health and its impact on treatment and product decisions. For topics and available therapeutic segmentations (100+), visit http://www.manhattanresearch.com/cch

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...